There have been no open-market insider trades at Cytek Biosciences, Inc. in the last 12 months.
On the institutional side, 155 funds reported holding CTKB at the end of Q2 2026, and more funds sold than bought. Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Jun 3, 2025 | McCombe William D. | CFO | Buy | 35,000 | $2.78 | $97K | SEC |
| Apr 23, 2024 | Yan Ming | Executive Officer | Sell | 20,000 | $5.87 | $117K | SEC |
| Apr 11, 2024 | Yan Ming | Executive Officer | Sell | 400 | $7.01 | $3K | SEC |
| Apr 11, 2024 | Yan Ming | Executive Officer | Sell | 1,500 | $7.00 | $10K | SEC |
| Mar 19, 2024 | Yan Ming | Executive Officer | Sell | 20,000 | $6.77 | $135K | SEC |
| Mar 19, 2024 | Yan Ming | Executive Officer | Sell | 20,000 | $6.71 | $134K | SEC |
| Dec 27, 2023 | Jeanmonod Patrik | CFO | Sell | 3,000 | $9.50 | $28K | SEC |
| Dec 21, 2023 | Yan Ming | Executive Officer | Sell | 20,000 | $9.43 | $189K | SEC |
| Nov 27, 2023 | Jeanmonod Patrik | CFO | Sell | 3,000 | $6.94 | $21K | SEC |
| Nov 21, 2023 | Yan Ming | Executive Officer | Sell | 20,000 | $6.03 | $121K | SEC |
| Nov 8, 2023 | Jiang Wenbin | CEO | Sell | 20,000 | $4.34 | $87K | SEC |
| Oct 25, 2023 | Jeanmonod Patrik | CFO | Sell | 3,000 | $4.68 | $14K | SEC |
| Oct 23, 2023 | Yan Ming | Executive Officer | Sell | 20,000 | $4.80 | $96K | SEC |
| Oct 11, 2023 | Jiang Wenbin | CEO | Sell | 20,000 | $5.33 | $107K | SEC |
| Sep 26, 2023 | Jeanmonod Patrik | CFO | Sell | 3,000 | $6.38 | $19K | SEC |
There were no open-market insider trades in CTKB in the last 12 months. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
155 investment managers reported holding CTKB in SEC Form 13F filings for Q2 2026.
No congressional trades in CTKB were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).